[Fundamental and clinical evaluation of imipenem/cilastatin sodium in the field of pediatrics]. 1986

T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi

A combination drug of imipenem (MK-0787), a new carbapenem antibiotic, and cilastatin sodium (MK-0791) at a ratio of 1:1 was used to treat infections in 8 children, and the concentrations of MK-0787 were determined in plasma, urine and pus of 1 patient and in cerebrospinal fluid of another patient. Eight patients, aged 2 months to 12 years (males: 3, females: 5), were treated with MK-0787/MK-0791. They consisted of 3 with urinary tract infections (causative organisms: E. coli, K. oxytoca plus E. faecalis, and unknown), and 1 patient each with pneumonia (H. influenzae), enteritis (Salmonella C1), cellulitis (S. aureus), purulent lymphadenitis (unknown) and purulent meningitis (E. coli). The dose, ranging from 7.4 mg/7.4 mg/kg to 11.8 mg/11.8 mg/kg, 3 or 4 times daily, was administered by a 30-minute or 60-minute intravenous drip infusion for 5 to 11 days. To the patient with purulent meningitis, however, 25.85 mg/25.85 mg/kg on the 1st day and 12.9 mg/12.9 mg/kg from the 2nd day were administered 4 times daily. Clinical responses in urinary tract infections were excellent in 2 and good in 1, and responses in pneumonia, enteritis, cellulitis, purulent lymphadenitis and purulent meningitis were excellent, good, good, excellent and poor, respectively. The efficacy rate in a total of 8 patients was 87.5%. As adverse reactions, a rash was observed in one patient and a convulsion in another. The rash disappeared after discontinuation of the administration of the drug and the convulsion stopped after a reduction of the dosage. As abnormal laboratory findings, slight prolongation of the prothrombin time was observed in 1 patient, but no bleeding tendency was noted. When MK-0787/MK-0791 (500 mg/500 mg, or 8.7 mg/8.7 mg/kg) was given by a 60-minute intravenous drip infusion to a 12-year-old boy with cellulitis, the peak plasma concentration of MK-0787 was 31.4 micrograms/ml occurring at the end of the infusion, and then the concentration decreased to 13.9 micrograms/ml in 0.5 hour, 8.9 micrograms/ml in 1 hour, 2.8 micrograms/ml in 2 hours, 0.63 microgram/ml in 4 hours and 0.14 microgram/ml in 6 hours. The half-life was 0.83 hour. These plasma levels provided concentrations exceeding MIC90's against major infective bacteria for 2 hours. The urinary recovery in the first 7 hours was 75.0%, and the urinary concentration was greater than 100 micrograms/ml for 5 to 7 hours.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D003875 Drug Eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. Dermatitis Medicamentosa,Dermatitis, Adverse Drug Reaction,Maculopapular Drug Eruption,Maculopapular Exanthem,Morbilliform Drug Reaction,Morbilliform Exanthem,Drug Eruption,Drug Eruption, Maculopapular,Drug Eruptions, Maculopapular,Drug Reaction, Morbilliform,Drug Reactions, Morbilliform,Eruption, Drug,Eruption, Maculopapular Drug,Eruptions, Drug,Eruptions, Maculopapular Drug,Exanthem, Maculopapular,Exanthem, Morbilliform,Exanthems, Maculopapular,Exanthems, Morbilliform,Maculopapular Drug Eruptions,Maculopapular Exanthems,Morbilliform Drug Reactions,Morbilliform Exanthems,Reaction, Morbilliform Drug,Reactions, Morbilliform Drug
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
July 1986, The Japanese journal of antibiotics,
T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
July 1986, The Japanese journal of antibiotics,
T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
July 1986, The Japanese journal of antibiotics,
T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
July 1986, The Japanese journal of antibiotics,
T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
July 1986, The Japanese journal of antibiotics,
T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
July 1986, The Japanese journal of antibiotics,
T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
November 1988, The Japanese journal of antibiotics,
T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
July 1986, The Japanese journal of antibiotics,
T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
July 1986, The Japanese journal of antibiotics,
T Haruta, and K E Okura, and S Kuroki, and H Yamamoto, and K Yamaoka, and K Kubo, and Y Kobayashi
May 1986, The Japanese journal of antibiotics,
Copied contents to your clipboard!